Methods of treating cancer

Abstract

The present invention relates to methods of treating or preventing cancer in a subject in need thereof comprising administering a therapeutically effective amount of a compound of the invention.

1 . A method of treating or preventing cancer in a subject in need thereof comprising administering a therapeutically effective amount of a FXR agonist selected from Compound 1 or 2: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt or amino acid conjugate thereof. 
     
     
         2 . The method of  claim 1 , wherein the cancer is selected from hepatocellular carcinoma, pancreatic cancer, kidney cancer, prostate cancer, esophageal cancer, breast cancer, gastric cancer, renal cancer, salivary gland cancer, ovarian cancer, uterine body cancer, bladder cancer, and lung cancer. 
     
     
         3 . The method of  claim 1  or  2 , wherein the cancer is hepatocellular carcinoma. 
     
     
         4 . The method of  claim 3 , wherein the hepatocellular carcinoma is selected from the group consisting of early stage hepatocellular carcinoma, non-metastatic hepatocellular carcinoma, primary hepatocellular carcinoma, advanced hepatocellular carcinoma, locally advanced hepatocellular carcinoma, metastatic hepatocellular carcinoma, hepatocellular carcinoma in remission, or recurrent hepatocellular carcinoma. 
     
     
         5 . The method of any one of  claims 1 - 4 , wherein the FXR agonist is Compound 1 or a pharmaceutically acceptable salt thereof. 
     
     
         6 . The method of  claim 5 , wherein the FXR agonist is the sodium salt of Compound 1. 
     
     
         7 . The method of  claim 5 , wherein the FXR agonist is the N,N-diethaneamine salt of Compound 1. 
     
     
         8 . The method of any one of  claims 1 - 4 , wherein the FXR agonist is Compound 2 or a pharmaceutically acceptable salt or amino acid conjugate thereof. 
     
     
         9 . The method of  claim 8 , wherein the FXR agonist is the glycine conjugate of Compound 2. 
     
     
         10 . The method of  claim 8 , wherein the FXR agonist is the taurine conjugate of Compound 2. 
     
     
         11 . The method of  claim 8 , wherein the FXR agonist is the sarcosine conjugate of Compound 2. 
     
     
         12 . A pharmaceutical composition comprising a FXR agonist selected from Compound 1 or 2: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt or amino acid conjugate thereof, for treating or preventing cancer in a subject in need thereof and a pharmaceutically acceptable excipient. 
     
     
         13 . A kit for treating or preventing cancer in a subject in need thereof comprising Compound 1 or Compound 2: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt or amino acid conjugate thereof. 
     
     
         14 . Use of a FXR agonist selected from Compound 1 or 2: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt or amino acid conjugate thereof in the manufacture of a medicament for treating or preventing cancer in a subject in need thereof.